-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Pyxis Oncology, Lowers Price Target to $7

Benzinga·11/06/2026 16:57:55
Listen to the news
Wedbush analyst Robert Driscoll maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and lowers the price target from $8 to $7.